Does UPMC Health Plan Cover Dupixent?

What Is Dupixent and Why Does UPMC Require Prior Authorization?

Dupixent (dupilumab) is a fully human monoclonal antibody that blocks the interleukin-4 and interleukin-13 signaling pathway, which drives type 2 inflammation in multiple chronic conditions. The FDA first approved dupilumab in March 2017 for moderate-to-severe atopic dermatitis in adults, and the approved population has expanded steadily since then to include children as young as 6 months old as of 2023 [1]. Because the drug costs approximately $37,000 to $45,000 per year at list price, every major insurer, including UPMC Health Plan, places it on a specialty formulary tier and requires prior authorization (PA) before dispensing [2].

Prior authorization exists to confirm medical necessity and to verify that lower-cost alternatives have been tried. UPMC Health Plan follows clinical coverage criteria aligned with FDA labeling and, for atopic dermatitis, with American Academy of Dermatology (AAD) guidelines that define moderate-to-severe disease by IGA score, BSA involvement, and inadequate response to topical therapies [3].

Why Biologic Step Therapy Is Standard Practice

Most commercial and managed Medicaid plans apply step-therapy protocols before approving biologics. For atopic dermatitis, UPMC typically requires documented failure of at least one medium-to-high-potency topical corticosteroid and, in many adult cases, a trial of a systemic immunosuppressant such as methotrexate or cyclosporine. A 2023 analysis in JAMA Dermatology found that step-therapy requirements delayed biologic initiation by a median of 4.6 months across major U.S. Insurers [4].

UPMC Formulary Placement

Dupixent sits on Specialty Tier 4 or Tier 5 across UPMC commercial products. Tier placement determines the coinsurance rate a member pays after meeting their deductible. Under most UPMC Advantage (Medicare) products, specialty drugs carry a 25% to 33% coinsurance during the initial coverage phase, which the manufacturer copay program cannot offset for Medicare beneficiaries due to federal anti-kickback rules.

Which Dupixent Indications Does UPMC Cover?

UPMC Health Plan writes separate PA criteria for each FDA-approved indication. Coverage is not automatic for a new indication simply because the drug was previously approved for a different condition. Below is a summary by indication.

Atopic Dermatitis (Eczema)

This is the most commonly requested indication. The FDA approved dupilumab for adults with moderate-to-severe atopic dermatitis not adequately controlled by topical therapies in 2017 [1]. Approval extended to adolescents (12 to 17 years) in 2019 and to children aged 6 months to 11 years in 2023.

UPMC PA criteria for atopic dermatitis generally require:

• A diagnosis of moderate-to-severe disease confirmed by a dermatologist or allergist
• IGA score of 3 or 4, or BSA involvement of 10% or more
• Documented failure of a topical corticosteroid of at least medium potency used for a minimum of 4 to 8 weeks
• For adults: documented trial of a systemic agent (methotrexate, cyclosporine, mycophenolate) unless contraindicated

The SOLO-1 and SOLO-2 trials (combined N=1,379) showed that dupilumab 300 mg every two weeks produced an IGA 0 or 1 response in 37% to 38% of patients versus 8% to 10% with placebo at 16 weeks (P<0.001) [5]. These trial data are the clinical foundation insurers use when writing coverage criteria.

Moderate-to-Severe Asthma With Type 2 Inflammation

The FDA approved dupilumab for add-on maintenance therapy in patients aged 6 and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or oral corticosteroid dependence [6]. UPMC PA for this indication typically requires:

• Blood eosinophil count of 150 cells/mcL or higher, or FeNO of 25 ppb or higher
• Current use of a medium-to-high-dose inhaled corticosteroid plus a long-acting beta-agonist
• Documentation that asthma is uncontrolled despite maximal inhaler therapy

The LIBERTY ASTHMA QUEST trial (N=1,902) showed that dupilumab 200 mg every two weeks reduced severe exacerbation rates by 48% and improved FEV1 by 0.14 L at 52 weeks versus placebo in patients with baseline eosinophils of 300 cells/mcL or higher [7].

Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)

The FDA approved dupilumab for CRSwNP in adults in June 2019 [8]. UPMC typically requires:

• Bilateral nasal polyps confirmed by nasal endoscopy or imaging
• Current or prior use of intranasal corticosteroids for at least 4 weeks
• Inadequate response to nasal corticosteroids and/or prior sinus surgery

Eosinophilic Esophagitis (EoE)

FDA approval for EoE in patients 12 and older came in May 2022 [9]. This is a gastroenterology-managed indication. UPMC PA requires a confirmed EoE diagnosis by esophageal biopsy showing at least 15 eosinophils per high-power field, plus documented failure of dietary elimination or proton pump inhibitor therapy.

Prurigo Nodularis

The FDA approved dupilumab for prurigo nodularis in adults in September 2022 [10]. Coverage criteria require moderate-to-severe disease, typically defined by a Worst Itch Numeric Rating Scale (WI-NRS) score of 7 or above, plus inadequate response to topical therapies.

COPD With Type 2 Inflammation

In September 2024, the FDA approved dupilumab as the first biologic for adults with uncontrolled COPD accompanied by type 2 inflammation, defined by blood eosinophil count of 300 cells/mcL or higher [11]. UPMC coverage criteria for this indication are still being finalized as of mid-2025, and PAs are being evaluated case-by-case.

How to Submit a Prior Authorization to UPMC Health Plan for Dupixent

Getting PA right the first time is faster than appealing a denial. The process has four concrete steps.

Step 1: Gather Documentation Before Submission

Your prescribing clinician's office initiates the PA, not the patient. Collect these before submitting:

• Office notes documenting disease severity scores (IGA, BSA, EASI, ACQ, NPS as appropriate)
• Lab results showing eosinophil count or FeNO for asthma/COPD indications
• Biopsy or imaging reports for EoE or CRSwNP
• Pharmacy records or chart notes proving prior failed therapies with dates and durations
• A letter of medical necessity from the treating specialist

Step 2: Submit Through UPMC's Provider Portal

UPMC Health Plan accepts PA requests through its NaviNet or Availity provider portals, by fax to UPMC's specialty pharmacy PA department, or via the specialty pharmacy CuraScript or AllianceRx Walgreens (both UPMC-contracted specialty pharmacies). Electronic submission typically produces a decision within 3 to 5 business days. Fax submissions average 7 to 14 days.

Step 3: Respond Promptly to Peer-to-Peer Requests

If UPMC's medical director requests a peer-to-peer call, schedule it within 48 hours. A 2022 survey published in the Journal of the American Academy of Dermatology found that peer-to-peer reviews overturned initial PA denials for biologics in 34% of cases when the treating physician participated directly [12].

Step 4: Confirm Specialty Pharmacy Routing

Dupixent is a specialty drug and cannot be dispensed at a standard retail pharmacy. UPMC Health Plan routes Dupixent through its preferred specialty pharmacy network. Confirm dispensing pharmacy selection before the PA closes to avoid a refill delay.

What Happens If UPMC Denies Your Dupixent Prior Authorization?

A denial is not the end of the process. Pennsylvania insurance law and federal Affordable Care Act regulations give members specific rights.

Internal Appeal

Members have 180 days from the denial date to file an internal appeal with UPMC Health Plan. Submit a written appeal with supplemental clinical evidence: updated severity scores, additional specialist notes, and any peer-reviewed literature supporting medical necessity. The AAD's position statement on dupilumab describes it as the standard of care for moderate-to-severe atopic dermatitis unresponsive to conventional therapy [3], a document worth including in the appeal packet.

External Review

If the internal appeal is denied, Pennsylvania's Act 68 (the Quality Health Care Accountability and Protection Act) guarantees the right to an independent external review by a state-certified independent review organization (IRO). The IRO's decision is binding on UPMC Health Plan. External review overturns insurance denials in approximately 39% to 45% of dermatology biologic cases nationally, based on data compiled by the Kaiser Family Foundation [13].

Expedited Appeal for Urgent Cases

If waiting 14 to 30 days for a standard appeal would seriously jeopardize health or the ability to receive ongoing treatment, members can request an expedited appeal. UPMC Health Plan must respond within 72 hours under CMS managed care rules applicable to its Medicaid and Medicare Advantage products [14].

How Much Will Dupixent Cost Under UPMC Coverage?

Even with an approved PA, out-of-pocket costs vary significantly by plan type.

Commercial UPMC Plans

Under commercial UPMC plans, Dupixent sits on a specialty tier with coinsurance typically ranging from 20% to 40% after the deductible. The Sanofi/Regeneron Dupixent MyWay program caps out-of-pocket costs at $0 per month for eligible commercially insured patients who meet income criteria, or reduces costs to a maximum of $300 per fill for those who do not qualify for the $0 tier [15]. Enrollment takes approximately 10 to 15 minutes at dupixent.com/myway.

UPMC for You (Medicaid)

Pennsylvania Medicaid (including UPMC for You) covers Dupixent for approved indications with a nominal copay of $1 to $4 per prescription for most members. PA criteria are slightly stricter under Medicaid, and step-therapy documentation must be thorough.

UPMC for Life (Medicare Advantage)

Medicare Part D rules prohibit manufacturer copay cards from applying to out-of-pocket costs. Under the Inflation Reduction Act's $2,000 annual cap on Part D out-of-pocket spending, which took full effect in 2025, many UPMC for Life members will reach their cap before exhausting their Dupixent supply for the year [16]. Members who qualify for the Low-Income Subsidy (LIS/Extra Help) program pay $0 to $11.20 per fill regardless of drug tier.

The table below outlines the typical cost structure across UPMC plan types. Use it as a starting reference; actual cost share depends on your specific plan year benefits.

| UPMC Plan Type | PA Required | Formulary Tier | Typical Member Cost | Copay Assistance Eligible | |---|---|---|---|---| | Commercial PPO/HMO | Yes | Specialty Tier 4/5 | 20-40% coinsurance | Yes (Dupixent MyWay) | | UPMC for You (Medicaid) | Yes | Covered/PA | $1-$4/fill | No (prohibited) | | UPMC for Life (Medicare Advantage) | Yes | Specialty Tier 4/5 | Up to $2,000/year cap | No (prohibited) | | UPMC Health Plan CHIP | Yes | Specialty | Minimal copay | No |

Dupixent MyWay Patient Support Program

Sanofi and Regeneron operate Dupixent MyWay as a dedicated support program covering financial assistance, injection training, and care coordination. For commercially insured patients whose PA is approved by UPMC, MyWay enrollment can reduce monthly out-of-pocket costs to $0 if household income is at or below 600% of the federal poverty level, or to a $300 maximum per fill for those above that threshold [15].

MyWay also provides:

• A dedicated nurse educator for injection technique
• Refill reminders and specialty pharmacy coordination
• Bridge supply of up to 90 days for patients awaiting PA decisions, subject to eligibility

The bridge supply option is clinically meaningful. Dupilumab shows detectable improvement in EASI score within 2 to 4 weeks of initiation in atopic dermatitis, and interrupting therapy before 16 weeks has been associated with partial loss of response in real-world cohort data [17].

Clinical Evidence Supporting Dupixent Coverage Requests

Including published trial data in a PA or appeal submission strengthens the medical necessity argument considerably. Below are the most relevant trials by indication.

Atopic Dermatitis: SOLO and CHRONOS Trials

The CHRONOS trial (N=740) extended dupilumab assessment to 52 weeks and showed sustained IGA 0/1 responses in 39% of the dupilumab-plus-topical-corticosteroid group versus 12% with placebo plus TCS (P<0.001) [18]. Sustained response data help counter step-therapy requirements by demonstrating long-term superiority over topical-only regimens.

Asthma: LIBERTY ASTHMA TRAVERSE

The open-label TRAVERSE extension trial (N=2,282) showed that the annualized severe exacerbation rate remained 73% lower in patients continuing dupilumab for up to 96 weeks compared with historical rates on standard of care [19]. Long-term extension data are persuasive in appealing step-therapy denials that assume biologics lose effect over time.

EoE: LIBERTY EoE TREET

The LIBERTY EoE TREET trial (N=321) showed histologic remission (fewer than 6 eosinophils/hpf) in 25% of dupilumab patients versus 6% with placebo at 24 weeks (P<0.001), and symptom improvement measured by the Dysphagia Symptom Questionnaire confirmed a clinically meaningful benefit [9].

Practical Tips From the HealthRX Clinical Team

The following recommendations reflect common patterns seen when navigating specialty biologic PA processes across major Pennsylvania insurers.

1. Submit PA through a board-certified dermatologist, allergist, or pulmonologist rather than a primary care provider. Specialist-initiated PAs have a measurably higher first-pass approval rate for biologics because they carry the clinical authority to document severity criteria.

2. Document every failed therapy with start date, stop date, dose used, and reason for discontinuation. Vague notes such as "patient tried topical steroids without benefit" are the leading cause of PA delay.

3. Request a formulary exception in writing simultaneously with the PA if your plan product has a non-formulary designation for Dupixent in a specific indication. Formulary exceptions run on a parallel track and do not reset appeal timelines.

4. If you are on UPMC for Life and worried about cost, contact the Pennsylvania SHIP (State Health Insurance Assistance Program) at 1-800-783-7067. SHIP counselors provide free, unbiased help determining whether Low-Income Subsidy qualification would reduce your Dupixent cost share to near zero.

5. Ask the specialty pharmacy to process a 90-day supply rather than 30-day fills once coverage is confirmed. A 90-day fill typically reduces total annual copay exposure under UPMC commercial plans by one coinsurance event.

Pennsylvania-Specific Regulatory Protections

Pennsylvania provides several statutory protections that affect UPMC Health Plan's coverage obligations for specialty drugs.

The Pennsylvania Insurance Department enforces Act 146 of 2016, which requires health insurers to make step-therapy exceptions within 72 hours (or 24 hours for urgent requests) when a prescriber certifies that the required step-therapy drug is contraindicated, has previously been tried and failed, or would cause clinically significant adverse effects [20]. This law directly applies to UPMC Health Plan's commercial products and is a powerful tool when documented contraindications to topical immunosuppressants or systemic agents exist.

Pennsylvania also adopted the federal 21st Century Cures Act transparency provisions, which require UPMC to disclose PA criteria upon member request. You are legally entitled to the exact clinical criteria UPMC is using to evaluate your Dupixent PA.